---
title: "Protara Therapeutics CEO Jesse Shefferman disposes of 215,687 common shares for $882,156.83"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/291457056.md"
description: "Protara Therapeutics CEO Jesse Shefferman reduced his direct common stock holdings by selling 215,687 shares at $4.09 each and gifting 30,000 shares on June 29-30. Following these transactions, his remaining stake stands at 691,832 shares."
datetime: "2026-07-01T20:11:05.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/291457056.md)
  - [en](https://longbridge.com/en/news/291457056.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/291457056.md)
---

# Protara Therapeutics CEO Jesse Shefferman disposes of 215,687 common shares for $882,156.83

-   Protara Therapeutics CEO and President Jesse Shefferman cut his direct common stock stake to 691,832 shares in transactions dated June 29-30. \* Sold 215,687 shares at USD 4.09, following an option exercise for 215,687 shares at USD 1.91 on June 29. \* Disposed of 30,000 additional shares as gifts on June 30 at USD 0. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Protara Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001213900-26-074238), on July 01, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here

### Related Stocks

- [TARA.US](https://longbridge.com/en/quote/TARA.US.md)

## Related News & Research

- [Protara Therapeutics (NASDAQ:TARA) Downgraded to Strong Sell Rating by Wall Street Zen](https://longbridge.com/en/news/295992564.md)
- [Protara Therapeutics: Strategic Trial Shift and Strong Cash Runway Support Buy Rating Despite Price Target Cut to $20 From $26](https://longbridge.com/en/news/295589045.md)
- [Protara Therapeutics Q2 net loss widens on higher expenses](https://longbridge.com/en/news/295534784.md)
- [Assenagon Asset Management S.A. Sells 507,667 Shares of Protara Therapeutics, Inc. $TARA](https://longbridge.com/en/news/296068027.md)
- [POSCO unit POSCO sets interim cash dividend at KRW 687 a share](https://longbridge.com/en/news/296227775.md)